Reported Sunday, Johnson & Johnson Unveils Long-Term Data From MARIPOSA Study Showing RYBREVANT Plus LAZCLUZE Outperforming Osimertinib In Lung Cancer Treatment
Reported Sunday, Johnson & Johnson Unveils Long-Term Data From MARIPOSA Study Showing RYBREVANT Plus LAZCLUZE Outperforming Osimertinib In Lung Cancer Treatment
週日報道，強生公佈了MARIPOSA研究的長期數據，顯示RYBREVANt加LAZCLUZE在肺癌治療中優於奧西替尼。
- New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT plus LAZCLUZE regimen compared to osimertinib monotherapy as first-line therapy
- Results from an interim analysis featured in late-breaker oral presentation at WCLC
- At three years (a median follow-up of 31.1 months), 61 percent of patients receiving RYBREVANT plus LACLUZE were alive compared to 53 percent of those treated with osimertinib based on an analysis performed at the request of a health authority (Median OS not estimable vs 37.3 months; hazard ratio [HR], 0.77; [95 percent confidence interval [CI], 0.61-0.96]; nominal P=0.019). Overall survival will continue to be assessed with longer term follow-up as a key secondary endpoint. The primary efficacy outcome measure was progression-free survival (PFS) as assessed by blinded independent central review (BICR).1
- MARIPOSA研究的最新長期數據證實，與奧西米替尼單藥療法作爲一線治療相比，RYBREVENT加LAZCLUZE方案在優越效果上有所確認
- WCLC中突破性口頭報告中呈現的中期分析結果
- 在三年時間（中位隨訪時間爲31.1個月）內，根據一項衛生主管機構請求進行的分析，接受RYBREVENT加LACLUZE治療的患者中，61％存活，而奧西米替尼治療的患者中爲53％（中位總生存期不可估算 vs 37.3個月；風險比[HR]，0.77； [95％置信區間[CI]，0.61-0.96]; 名義P=0.019）。總生存將繼續通過更長期的隨訪作爲關鍵次要終點進行評估。主要療效終點措施爲由盲法獨立中心審查（BICR）評估的無進展生存（PFS）。
資訊熱榜
更新時間